Home › Targets › BCMA

BCMA (9 companies · 16 programs)

Companies with an active program directed at BCMA.

Cartesian Therapeutics, Inc. RNAC

Descartes-08 — Myasthenia Gravis Phase 3
Descartes-08 — Dermatomyositis Phase 1
Descartes-08 — Antisynthetase Syndrome Phase 2
Descartes-15 — Multiple Myeloma Phase 1

Cullinan Therapeutics, Inc. CGEM

velinotamig — Systemic Lupus Erythematosus Phase 1
velinotamig — Immune Thrombocytopenia Preclinical
velinotamig — Autoimmune Hemolytic Anemia Preclinical

Autolus Therapeutics plc AUTL

AUTO8 — Relapsed/Refractory Multiple Myeloma Phase 1
AUTO8 — Light Chain Amyloidosis Phase 1

Legend Biotech Corp LEGN

CARVYKTI — Relapsed/Refractory Multiple Myeloma Approved
LB2405 Phase 1

Allogene Therapeutics, Inc. ALLO

ALLO-715 — Multiple Myeloma Phase 1

Caribou Biosciences, Inc. CRBU

CB-011 — Relapsed/Refractory Multiple Myeloma Phase 1

Immix Biopharma, Inc. IMMX

NXC-201 — Relapsed/Refractory AL Amyloidosis Phase 1

MiNK Therapeutics, Inc. INKT

MiNK-413 Preclinical

Sana Biotechnology, Inc. SANA

SG227 — Multiple Myeloma Preclinical